全文获取类型
收费全文 | 10495篇 |
免费 | 494篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 159篇 |
儿科学 | 733篇 |
妇产科学 | 208篇 |
基础医学 | 1127篇 |
口腔科学 | 185篇 |
临床医学 | 638篇 |
内科学 | 2391篇 |
皮肤病学 | 252篇 |
神经病学 | 488篇 |
特种医学 | 471篇 |
外科学 | 1624篇 |
综合类 | 256篇 |
一般理论 | 7篇 |
预防医学 | 458篇 |
眼科学 | 342篇 |
药学 | 695篇 |
中国医学 | 59篇 |
肿瘤学 | 931篇 |
出版年
2023年 | 66篇 |
2022年 | 153篇 |
2021年 | 347篇 |
2020年 | 193篇 |
2019年 | 221篇 |
2018年 | 286篇 |
2017年 | 219篇 |
2016年 | 271篇 |
2015年 | 312篇 |
2014年 | 424篇 |
2013年 | 535篇 |
2012年 | 782篇 |
2011年 | 874篇 |
2010年 | 482篇 |
2009年 | 434篇 |
2008年 | 627篇 |
2007年 | 660篇 |
2006年 | 632篇 |
2005年 | 561篇 |
2004年 | 500篇 |
2003年 | 398篇 |
2002年 | 409篇 |
2001年 | 130篇 |
2000年 | 161篇 |
1999年 | 124篇 |
1998年 | 93篇 |
1997年 | 74篇 |
1996年 | 64篇 |
1995年 | 49篇 |
1994年 | 27篇 |
1993年 | 38篇 |
1992年 | 86篇 |
1991年 | 72篇 |
1990年 | 84篇 |
1989年 | 68篇 |
1988年 | 58篇 |
1987年 | 57篇 |
1986年 | 53篇 |
1985年 | 61篇 |
1984年 | 50篇 |
1983年 | 26篇 |
1981年 | 31篇 |
1980年 | 19篇 |
1979年 | 27篇 |
1978年 | 23篇 |
1977年 | 13篇 |
1976年 | 11篇 |
1975年 | 13篇 |
1971年 | 13篇 |
1969年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
121.
Mohan V Meera R Premalatha G Deepa R Miranda P Rema M 《Postgraduate medical journal》2000,76(899):569-573
The frequency of proteinuria was assessed in a cohort of 1848 diabetic patients attending a diabetes centre in south India. A total of 127 (6.9%) patients had evidence of macroproteinuria and 49 (2.5%) patients had microproteinuria. Thus overall 9.4% of patients had diabetes related proteinuria. In addition, 70 patients (3.8%) had evidence of proteinuria with no evidence of retinopathy. The frequency of both microproteinuria and macroproteinuria increased linearly with duration of diabetes. Multiple logistic regression analysis showed that duration of diabetes, serum creatinine, and glycated haemoglobin were risk factors for macroproteinuria. 相似文献
122.
Rakesh K Mondal Sunit C Singhi Arunaloke Chakrabarti Jayashree M 《Pediatric critical care medicine》2004,5(6):561-565
OBJECTIVE: Candida bloodstream infections have shown an increase in hospitalized patients, especially those receiving intensive care. The effectiveness of various azoles, especially itraconazole, in treatment of candidemia has not been fully evaluated. Our objective was to compare the efficacy and safety of enterally administered itraconazole vs. fluconazole in treatment of candidemia. DESIGN: Randomized, double-blind, controlled trial. SETTING: Pediatric intensive care unit of a referral and teaching hospital. SUBJECTS: Forty-three pediatric patients with candidemia, INTERVENTION: Patients received either fluconazole (n = 22) or itraconazole (n = 21), about 10 mg/kg orally or through a gastric tube, and were monitored for clinical and mycological cure (sterile fungal blood culture), blood counts, and liver and renal functions. MEASUREMENTS AND MAIN RESULTS: The clinical characteristics of two groups were comparable. The cure rate was similar in both the groups: itraconazole 17 of 21 (81%) and fluconazole 18 of 22 (82%). Crude mortality rate (itraconazole 9.5% and fluconazole 13.6%) was also comparable in two groups of patients. The frequency of electrolyte disturbance was very low and similar in both the groups. Blood urea, creatinine, liver enzymes, and serum bilirubin were not adversely affected. CONCLUSIONS: Itraconazole was as effective as fluconazole in nosocomial candidiasis in children receiving intensive care and was devoid of serious side effects. 相似文献
123.
124.
Prahlad Duggal S. Chakravorty Ramesh K. Azad Chander Mohan 《Indian journal of otolaryngology and head and neck surgery》2006,58(4):349-351
Dacryocystorhinostomy is performed in patients with naso-lacrimal duct obstruction to bypass the site of obstruction so as
to relieve the patient of the irritating and socially embarrassing symptoms of epiphora. We discuss the various epidemiological
aspects especially the vast difference by which the females out-number the males in patients undergoing DCR and the likely
explanations for this difference in our study on 74 patients which underwent DCR in our institute. 相似文献
125.
Rakesh Jalali Ashwini Budrukkar Rajiv Sarin Dayananda S Sharma 《Radiotherapy and oncology》2005,74(1):37-44
BACKGROUND AND PURPOSE: To report local control and follow up outcome data of high precision conformal radiotherapy in childhood brain tumours. MATERIALS AND METHODS: Between December 1999 and December 2002, 26 children (17 boys and 9 girls, median age 11.5 years) with incompletely excised or recurrent benign and low-grade brain tumours [13 craniopharyngiomas, 11 low-grade gliomas (LGG) and 2 others] were treated with three-dimensional (3D) conformal radiotherapy (CRT) (12 patients) and stereotactic conformal radiotherapy (SCRT) (14 patients). Gross tumour volume (GTV) included neuro-imaging based visible tumour and/or resected tumour bed. Clinical target volume (CTV) consisted of GTV+ 5 mm margin and planning target volume (PTV) consisted of additional 5 mm margin for CRT and 2 mm for SCRT. Treatment was delivered with 3-9 conformal fixed fields to a median dose of 54 Gy/30 fractions. RESULTS: The actuarial 2 and 3 year disease free and overall survival was 96 and 100%, respectively (median follow up: 25 months, range 12-47 months). Radiological follow up available in 25 patients revealed complete response in 1, partial regression in 10, stable disease in 13 and progression in 1 patient (within the CTV). One patient with craniopharyngioma on a routine imaging revealed a mild asymptomatic cyst enlargement, which resolved with conservative management. A patient with chiasmatic glioma developed cystic degeneration and hydrocephalus 9 months after SCRT requiring cyst drainage and placement of a ventriculoperitoneal shunt. CONCLUSION: High-precision conformal techniques delivering irradiation to a computer generated target volume employing 7-10 mm 3D margins beyond the visible tumour and/or resected tumour bed appear to be safe in children with incompletely resected or recurrent benign and low-grade brain tumours, based on these data. 相似文献
126.
The clinical relevance of steroid hormone receptor corepressors. 总被引:2,自引:0,他引:2
Rakesh Kumar Anupama E Gururaj Ratna K Vadlamudi Suresh K Rayala 《Clinical cancer research》2005,11(8):2822-2831
127.
Mohan Kameswaran M. C. Vasudevan R. S. Anand Kumar Jawahar Nagasundaram Kiran Natarajan S. Raghunandhan 《Indian journal of otolaryngology and head and neck surgery》2005,57(1):58-63
Multichannel auditory brainstem implants (ABI) are currently indicated for patients with neurofibromatosis type II (NF2) involving both vestibulocochlear nerves. The ABI helps bypass the damaged cochlear nerves and restores a level of auditory sensation via the electrical stimulation of the cochlear nucleus. The implant is usually placed in the lateral recess of the fourth ventricle at the time of tumor resection to stimulate the cochlear nucleus. We report a case of ABI done on a 15-year-old girl with bilateral vestibular schwannomas. 相似文献
128.
129.
Christopher G Willett Yves Boucher Dan G Duda Emmanuelle di Tomaso Lance L Munn Ricky T Tong Sergey V Kozin Lucine Petit Rakesh K Jain Daniel C Chung Dushyant V Sahani Sanjeeva P Kalva Kenneth S Cohen David T Scadden Alan J Fischman Jeffrey W Clark David P Ryan Andrew X Zhu Lawrence S Blaszkowsky Paul C Shellito Mari Mino-Kenudson Gregory Y Lauwers 《Journal of clinical oncology》2005,23(31):8136-8139
130.
Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. 总被引:15,自引:0,他引:15
Activation of cell surface death receptors by their cognate ligands triggers apoptosis. Several human death receptors (Fas, TNF-R1, TRAMP, DR4, DR5, DR6, EDA-R and NGF-R) have been identified. The most promising cytokine for anticancer therapy is TRAIL/APO-2L, which induces apoptosis in cancer cells by binding to death receptors TRAIL-R1/DR4 and TRAIL-R2/DR5. The cytotoxic activity of TRAIL is relatively selective to cancer cells compared to normal cells. Signaling by TRAIL and its receptors is tightly regulated process essential for key physiological functions in a variety of organs, as well as the maintenance of immune homeostasis. Despite early promising results, recent studies have identified several TRAIL-resistant cancer cells of various origins. Based on molecular analysis of death-receptor signaling pathways several new approaches have been developed to increase the efficacy of TRAIL. Resistance of cancer cells to TRAIL appears to occur through the modulation of various molecular targets. They may include differential expression of death receptors, constitutively active Akt and NFkappaB, overexpression of cFLIP and IAPs, mutations in Bax and Bak genes, and defects in the release of mitochondrial proteins in resistant cells. Conventional chemotherapeutic and chemopreventive drugs, and irradiation can sensitize TRAIL-resistant cells to undergo apoptosis. Thus, these agents enhance the therapeutic potential of TRAIL in TRAIL-sensitive cells and sensitize TRAIL-resistant cells. TRAIL and TRAIL-receptor antibodies may prove to be useful for cancer therapy, either alone or in association with conventional approaches such as chemotherapy or radiation therapy. This review discusses intracellular mechanisms of TRAIL resistance and various approaches that can be taken to sensitize TRAIL-resistant cancer cells. 相似文献